Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6Fibrosis 3Lymphedema 2Head and Neck Neoplasms 2Sarcoidosis, Pulmonary 1Primary Ovarian Insufficiency 1Polycystic Ovary Syndrome 1Pain 1Non-small Cell Lung Cancers 1Mucositis 1Long-term Adverse Effects of Radiotherapy for Pelvic Cancer 1Erectile Dysfunction 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Cancer Female 1Brain Neoplasms 1

Interventions

Tadalafil 2udenafil 1mirabegron 1bicalutamide 1alpha-Tocopherol 1Vitamin E 1Tamoxifen 1Sildenafil Citrate 1Pentoxifylline 1Long-Term Synaptic Depression 1GPI 1485 1Erythropoietin 1Dutasteride 1Atorvastatin 1Arginine 1ArginMax 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Erectile Dysfunction × Pentoxifylline × Clear all
NCT03830164 2023-10-17

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
14 enrolled 9 charts

Erectile Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡